Connect with us

Hi, what are you looking for?


Wall Street analysts are bullish on Moderna stock price: should you?

Moderna (NASDAQ: MRNA) stock price will be in the spotlight on Monday after the company announced important outcome of its skin cancer vaccine. The shares, which closed at $157 on Friday, are expected to jump when the markets open. The stock remains ~28% below the highest point this year.

Moderna cancer vaccine hopes

Moderna has been under pressure in the past few months as the demand for its Covid-19 vaccine has evaporated. After making billions of dollars selling its Covid vaccine, Moderna expects that sales of this vaccine will be just $5 billion this year.

And recently, as we wrote here, the company made headlines when the company’s flu vaccine delivered mixed results in testing.

Therefore, focus is on the company’s cancer vaccine. The firm is researching the drug in collaboration with Merck & Co, one of the biggest companies in the pharmaceutical industry.

In a statement, the firm said that the drug had shown positive results in testing. The company said that about 79% of people who received the drug stayed cancer free for about 18 months. This was a bigger reading than the 62% of people who received Keytruda, a drug created by Merck. 

Therefore, the two companies will now need to move to a larger trial to prove that the combination of the vaccine and Keytuda works. The third phase of trial will start later this year and take a few months to complete. The statement added:

“These data support the potential of mRNA-4157 (V940) in combination with KEYTRUDA to help fight melanoma earlier and warrant investigation of the combination in a larger Phase 3 trial. We also look forward to studying mRNA-4157 (V940) and KEYTRUDA in a variety of other early-stage cancers.”

For now, the only reason to invest in Moderna is because of its pipeline of vaccines. According to its website, Moderna is building vaccines in the respiratory, adolescent and pediatrics, latent & public health vaccines, and therapeutics among others. Most of these vaccines are in testing, with approvals set to happen in the next few years.

Analysts have mixed views about the Moderna stock price. JP Mogan analysts recently boosted their view of the stock from $127 and $145. TD Cowen upgraded the stock to $180 while RBC increased their rating to $200.

Moderna stock price forecast

MRNA chart by TradingView

The daily chart shows that the MRNA stock price formed a strong bottom at $120.85. It has struggled to move below this level several times since February 2022. The shares are oscillating at the 50-day exponential moving average. It is also a few points below the 23.6% Fibonacci Retracement level.

The stock has formed a small ascending channel and an inverted cup and handle pattern. Therefore, there is a likelihood that the stock will rise after the new cancer vaccine news and then resume the bearish trend and retest the key support at $117.70.

The post Wall Street analysts are bullish on Moderna stock price: should you? appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.